Intoplicine dimesylate | CAS# 133711-99-6 | Biochemical

MedKoo Cat#: 576702 | Name: Intoplicine dimesylate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Intoplicine dimesylate is a DNA topoisomerase I and II inhibitor potentially for the treatment of cancer.

Chemical Structure

Intoplicine dimesylate

CAS#133711-99-6

Theoretical Analysis

MedKoo Cat#: 576702

Name: Intoplicine dimesylate

CAS#: 133711-99-6

Chemical Formula: C23H32N4O7S2

Exact Mass: 540.1712

Molecular Weight: 540.65

Elemental Analysis: C, 51.10; H, 5.97; N, 10.36; O, 20.71; S, 11.86

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Intoplicine dimesylate; RP 60475; RP60475; RP-60475

IUPAC/Chemical Name

11-((3-(dimethylamino)propyl)amino)-8-methyl-7H-benzo[e]pyrido[4,3-b]indol-3-ol dimethanesulfonate

InChi Key

JAUYMMJDKJISLX-UHFFFAOYSA-N

InChi Code

InChI=1S/C21H24N4O.2CH4O3S/c1-13-12-23-21(22-9-4-10-25(2)3)19-18-16-7-6-15(26)11-14(16)5-8-17(18)24-20(13)19;2*1-5(2,3)4/h5-8,11-12,24,26H,4,9-10H2,1-3H3,(H,22,23);2*1H3,(H,2,3,4)

SMILES Code

CN(C)CCCNc1ncc(C)c2[nH]c3ccc4cc(O)ccc4c3c12.CS(=O)(=O)O.CS(=O)(=O)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 540.65 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Denny WA, Baguley BC. Dual topoisomerase I/II inhibitors in cancer therapy. Curr Top Med Chem. 2003;3(3):339-53. Review. PubMed PMID: 12570767. 2: Etiévant C, Kruczynski A, Barret JM, Perrin D, van Hille B, Guminski Y, Hill BT. F 11782, a dual inhibitor of topoisomerases I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual topoisomerase inhibitors, intoplicin, aclarubicin and TAS-103. Cancer Chemother Pharmacol. 2000;46(2):101-13. PubMed PMID: 10972479. 3: Newman RA, Kim J, Newman BM, Bruno R, Bayssas M, Klink-Alaki M, Pazdur R. Phase I trial of intoplicine (RP 60475) administered as a 72 h infusion every 3 weeks in patients with solid tumors. Anticancer Drugs. 1999 Nov;10(10):889-94. PubMed PMID: 10630356. 4: van Gijn R, ten Bokkel Huinink WW, Rodenhuis S, Vermorken JB, van Tellingen O, Rosing H, van Warmerdam LJ, Beijnen JH. Topoisomerase I/II inhibitor intoplicine administered as a 24 h infusion: phase I and pharmacologic study. Anticancer Drugs. 1999 Jan;10(1):17-23. PubMed PMID: 10194543. 5: Utsugi T, Aoyagi K, Asao T, Okazaki S, Aoyagi Y, Sano M, Wierzba K, Yamada Y. Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II. Jpn J Cancer Res. 1997 Oct;88(10):992-1002. PubMed PMID: 9414662. 6: Guerquin-Kern JL, Coppey M, Carrez D, Brunet AC, Nguyen CH, Rivalle C, Slodzian G, Croisy A. Complementary advantages of fluorescence and SIMS microscopies in the study of cellular localization of two new antitumor drugs. Microsc Res Tech. 1997 Feb 15;36(4):287-95. PubMed PMID: 9140928. 7: Abigerges D, Armand JP, Chabot GG, Bruno R, Bissery MC, Bayssas M, Klink-Alakl M, Clavel M, Catimel G. Phase I and pharmacology study of intoplicine (RP 60475; NSC 645008), novel topoisomerase I and II inhibitor, in cancer patients. Anticancer Drugs. 1996 Feb;7(2):166-74. PubMed PMID: 8740721. 8: Hanauske AR, Clark GM, Von Hoff DD. Adenocarcinoma of unknown primary: retrospective analysis of chemosensitivity of 313 freshly explanted tumors in a tumor cloning system. Invest New Drugs. 1995;13(1):43-9. PubMed PMID: 7499107. 9: Nabiev I, Chourpa I, Riou JF, Nguyen CH, Lavelle F, Manfait M. Molecular interactions of DNA-topoisomerase I and II inhibitor with DNA and topoisomerases and in ternary complexes: binding modes and biological effects for intoplicine derivatives. Biochemistry. 1994 Aug 2;33(30):9013-23. PubMed PMID: 8043587. 10: Eckardt JR, Burris HA 3rd, Kuhn JG, Bissery MC, Klink-Alakl M, Clark GM, Von Hoff DD. Activity of intoplicine (RP60475), a new DNA topoisomerase I and II inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst. 1994 Jan 5;86(1):30-3. PubMed PMID: 8271279. 11: Von Hoff DD, Burris HA 3rd, Eckardt J, Rothenberg M, Fields SM, Chen SF, Kuhn JG. Preclinical and phase I trials of topoisomerase I inhibitors. Cancer Chemother Pharmacol. 1994;34 Suppl:S41-5. PubMed PMID: 8070026. 12: Weiss GR, Burris HA 3rd, Eckardt JR, Fields S, O'Rourke T, Rodriguez GI, Rothenberg ML. New anticancer agents. Cancer Chemother Biol Response Modif. 1994;15:130-51. Review. PubMed PMID: 7779583. 13: Riou JF, Fossé P, Nguyen CH, Larsen AK, Bissery MC, Grondard L, Saucier JM, Bisagni E, Lavelle F. Intoplicine (RP 60475) and its derivatives, a new class of antitumor agents inhibiting both topoisomerase I and II activities. Cancer Res. 1993 Dec 15;53(24):5987-93. PubMed PMID: 8261412. 14: Bissery MC, Nguyen CH, Bisagni E, Vrignaud P, Lavelle F. Antitumor activity of intoplicine (RP 60475, NSC 645008), a new benzo-pyrido-indole: evaluation against solid tumors and leukemias in mice. Invest New Drugs. 1993 Nov;11(4):263-77. PubMed PMID: 8157469. 15: van Gijn R, De Graaff-Teulen MJ, van Tellingen O, Beijnen JH. Chemical stability of the new antitumour agent intoplicine in infusion fluids. J Pharm Biomed Anal. 1993 Nov-Dec;11(11-12):1353-6. PubMed PMID: 8123754. 16: van Gijn R, Kuijs S, Rosing H, Dubbelman AC, van Tellingen O, ten Bokkel Huinink WW, Pinedo HM, Beijnen JH. Determination of intoplicine, a new antitumour drug, in human faeces by normal-phase high-performance liquid chromatography with fluorescence detection. J Pharm Biomed Anal. 1993 Nov-Dec;11(11-12):1345-8. PubMed PMID: 8123753. 17: Morjani H, Riou JF, Nabiev I, Lavelle F, Manfait M. Molecular and cellular interactions between intoplicine, DNA, and topoisomerase II studied by surface-enhanced Raman scattering spectroscopy. Cancer Res. 1993 Oct 15;53(20):4784-90. PubMed PMID: 8402662. 18: Poddevin B, Riou JF, Lavelle F, Pommier Y. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials. Mol Pharmacol. 1993 Oct;44(4):767-74. PubMed PMID: 8232227. 19: van Gijn R, Rosing H, ten Bokkel Huinink WW, van Tellingen O, Vermorken JB, Liefting AJ, Bruno R, Pinedo HM, Beijnen JH. Determination of intoplicine, a new antitumour drug, in human whole blood and plasma by normal-phase high-performance liquid chromatography with fluorescence detection. J Chromatogr. 1993 May 5;614(2):299-306. PubMed PMID: 8314943.